The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Nasopharyngeal Carriage

(2013) Katherine E. Fleming-Dutra et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

(2013) Daniel R. Feikin et al.   PLOS MEDICINE

The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: A randomized controlled trial

(2012) Ron Dagan et al.   VACCINE

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

(2012) M. H. Rozenbaum et al.   BMJ-British Medical Journal

Pneumococcal Carriage and Antibiotic Resistance in Young Children Before 13-valent Conjugate Vaccine

(2011) Peter C. Wroe et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom

(2010) David Goldblatt et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL